Tissue repair & recovery research
BPC-157: Research, Mechanism & Current Evidence
Synthetic gastric peptide widely studied in animal tissue-repair models, with very limited human data.
Also known as Body Protection Compound-157 · PL 14736 · pentadecapeptide BPC 157
What is BPC-157?
BPC-157 is a synthetic chain of fifteen amino acids based on a sequence found in a protein in human gastric juice. The name stands for Body Protection Compound. It does not occur naturally in this exact form — it is a stable fragment designed for laboratory work.
It is the most heavily discussed compound in tissue-repair research and simultaneously one of the least supported by human evidence, which is the tension any honest summary has to hold.
Status: Not an approved medicine. Prohibited at all times in sport by WADA under the S0 non-approved substances category.
What is BPC-157 researched for?
Published research covers tendon and ligament healing, muscle injury, gut protection against ulcers and inflammatory damage, blood vessel formation, and nerve injury including spinal cord models.
A recurring theme is protection against damage caused by non-steroidal anti-inflammatory drugs.
- Accelerated tendon-to-bone healing with improved biomechanical properties; most effective with localized injection.
- Enhanced healing and reduced recovery following crush injuries and surgical procedures with direct tissue targeting.
- Promotes blood vessel formation and improves vascularization through localized delivery.
- Protective effects against neurotoxic agents and ischemic brain injury models.
- Improved functional recovery and reduced tissue damage in spinal cord injury studies.
- Enhanced peripheral nerve regeneration and functional recovery after injury.
- Protective effects against gastric and duodenal ulcers through cytoprotective mechanisms.
- Acceleration of intestinal healing with reduced inflammatory markers in IBD models.
- Enhanced mucosal barrier function and accelerated epithelial regeneration.
How does BPC-157 work?
The mechanism most consistently reported is an effect on new blood vessel formation, called angiogenesis. Healing tissue needs a blood supply, and BPC-157 appears to increase signalling through the VEGFR2 receptor, which drives blood vessel growth.
Other reported effects include changes in collagen production, growth factor signalling and nitric oxide pathways. These are described in laboratory and animal systems; no mechanism has been confirmed in humans.
What does the research show?
The substantial body of evidence is preclinical. Rat studies from the 1990s onward report faster healing of transected Achilles tendon and quadriceps muscle, functional recovery after spinal cord injury, and protection of the gut lining. A 2020 preclinical safety evaluation across mice, rats, rabbits and dogs reported no serious toxicity.
Human evidence is minimal and recent: a 2024 pilot study in twelve women with interstitial cystitis, and a 2025 intravenous safety study in two healthy adults. Both are small, uncontrolled and published in the same journal.
Limitations of the current evidence
Rodent healing models translate poorly to humans as a general rule, and BPC-157 has no completed randomised controlled trial in any indication.
A clinical programme under the code PL 14736 was pursued for inflammatory bowel disease and did not proceed to approval.
Much of the preclinical literature originates from a small number of closely connected research groups, which limits how independent the replication is.
References
Staresinic M, Sebecic B, Patrlj L, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003
Superior tendon healing with improved biomechanical properties (increased load of failure and Young's modulus), enhanced tendon-to-bone integration, and stimulated tendocyte growth in rat models.
Animal study · PMID 14554208
Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157
Staresinic M, Petrovic I, Novinscak T, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2006
Accelerated quadriceps healing over 72-day period with improved biomechanics, walking recovery, muscle fiber regeneration with desmin positivity, and attenuated atrophy in rat models.
Animal study · PMID 16609979
Perovic D, Kolenc D, Bilic V, et al. · Journal of orthopaedic surgery and research · 2019
Significant functional recovery with improved motor function, resolved spasticity by day 15, and counteracted axonal necrosis, demyelination, and cyst formation across all stages of secondary injury.
Animal study · PMID 31266512
Park JM, Lee HJ, Sikiric P, et al. · Current pharmaceutical design · 2020
Cytoprotective effects against NSAID-induced gastric and intestinal damage by stabilizing intestinal permeability and protecting mucosal barrier function across multiple epithelia.
PMID 32445447
Hsieh MJ, Liu HT, Wang CN, et al. · Journal of molecular medicine (Berlin, Germany) · 2017
Pro-angiogenic effects via VEGFR2-Akt-eNOS signaling pathway activation, increased vessel density in vivo and in vitro, and accelerated blood flow recovery in ischemic rat hind limb model.
Animal study · PMID 27847966
Xu C, Sun L, Ren F, et al. · Regulatory toxicology and pharmacology : RTP · 2020
Well tolerated in mice, rats, rabbits, and dogs with no serious toxicity in single-dose, repeated-dose, local tolerance, genetic, or embryo-fetal toxicity studies.
Animal study · PMID 32334036
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Lee E, Walker C, Ayadi B · Alternative therapies in health and medicine · 2024
Pilot human trial in 12 women (ages 39-76) with interstitial cystitis showed BPC-157 as a potential treatment for this disabling condition with no effective existing therapies.
Early human study · PMID 39325560
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E, Burgess K · Alternative therapies in health and medicine · 2025
First human IV safety data: infusions of up to 20 mg BPC-157 in 2 healthy adults showed no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers.
Early human study · PMID 40131143
Common questions
What does the human evidence for BPC-157 actually consist of?
Two small pilot studies published in 2024 and 2025 — one in twelve women with interstitial cystitis, one an intravenous safety assessment in two healthy adults. Neither was randomised or placebo-controlled. There is no completed controlled clinical trial.
Why is BPC-157 so heavily researched in animals but not in people?
It is a short synthetic peptide that is inexpensive to make and difficult to patent in a commercially attractive form, which reduces the incentive to fund large trials. An earlier clinical programme for inflammatory bowel disease did not reach approval.
Is BPC-157 permitted in competitive sport?
No. WADA lists it as prohibited at all times under category S0, which covers substances with no current approval from any governmental regulatory health authority for human therapeutic use.